Guselkumab provides sustained domain-specific and comprehensive efficacy as assessed using composite endpoints in patients with active psoriatic arthritis free

Autor: Coates, LC, Ritchlin, CT, Gossec, L, Helliwell, P, Rahman, P, Hsia, EC, Kollmeier, A, Xu, XL, Karyekar, C, Shawi, M, Noel, W, Jiang, Y, Sheng, S, Wang, Y, Mease, PJ

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______1064::c02d2b289a4434dcecd7cb2fb49c133d
https://doi.org/10.1136/annrheumdis-2021-eular.167

PE.Di-018 - Amélioration durable des manifestations cutanées et de la fonction physique avec le sécukinumab versus l’ustékinumab chez les patients atteints de psoriasis modéré à sévère et de rhumatisme psoriasique concomitant : résultats de l’étude CLEAR à 1 an

Autor: Lacour, J.P. ⁽¹⁾, Ruer-Mulard, M. ⁽²⁾, Beylot-Barry, M. ⁽³⁾, Célerier, P. ⁽⁴⁾, Contreras, L. ⁽⁵⁾, Gottlieb, A.B ⁽⁶⁾, Karyekar, C. ⁽⁷⁾

Publikováno v: In Revue du rhumatisme November 2016 83 Supplement 1:A174-A174

Effect of St. John′s Wort extract on intestinal expression of cytochrome P4501A2: studies in LS180 cells

Autor: Karyekar C, Eddington N, Dowling T

Publikováno v: Journal of Postgraduate Medicine, Vol 48, Iss 2, Pp 97-100 (2002)

BACKGROUND AND AIMS: St. John′s Wort (SJW) is known to induce expression and activity of cytochrome P4503A4 (CYP3A4). However, its effects on other cytochrome P450 (CYP) are not well understood. Our objective was to characterise the effect of SJW o

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doajarticles::3fc19448aed8616e69f3f0241704a4e0
http://www.jpgmonline.com/article.asp?issn=0022-3859

Induction of clinical remission followed by drug-free withdrawal with abatacept combination and monotherapy in early RA: results from the AVERT (Assessing Very Early Rheumatoid arthritis Treatment) study over 18 months

Autor: Emery, P, Burmester, GR, Bykerk, V, Combe, B, Furst, D, Barre, E, Karyekar, C, Wong, D, Huizinga, T

Publikováno v: 42. Kongress der Deutschen Gesellschaft für Rheumatologie (DGRh); 28. Jahrestagung der Deutschen Gesellschaft für Orthopädische Rheumatologie (DGORh); 24. wissenschaftliche Jahrestagung der Gesellschaft für Kinder-und Jugendrheumatologie (GKJR); 20140917-20140920; Düsseldorf; DOCRA.04 /20140912/

Background: AVERT is a Phase IIIb, randomized, active-controlled study to evaluate the efficacy and safety of subcutaneous (SC) abatacept (ABA) in patients with early RA. We assessed ABA+MTX or ABA monotherapy in inducing clinical remission at 12 mon

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c1ea0bb2f3ecf15cb438aafba8ac53d0

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.